Introduction
Alzheimer's disease (AD) is a neurodegenerative disease of the brain associated with irreversible cognitive decline, memory impairment, and behavioral changes. Postmortem brains of AD patients reveal neuropathologic features: the presence of senile plaques (SPs) and neurofibrillary tangles (NFTs), which contain b-amyloid (Ab) peptides and highly phosphorylated tau proteins.
1,2) Although the precise mechanism of neuronal death in AD is still unknown, it is widely accepted that SPs and NFTs play a central role in its development. Currently, the only definitive confirmation of AD is by postmortem histopathologic examination of Ab deposits in the brain. Therefore Ab plaques in the brain may be useful as a biomarker for the differential diagnosis of AD, and the detection of individual Ab plaques in vivo by positron-emission tomography (PET) or single-photon emission computed tomography (SPECT) should improve diagnosis and also accelerate discovery of effective therapeutic agents for AD. [14] [15] [16] [17] [18] [19] [20] [21] (Fig. 1 ). This paper reviews research on the development of PET/SPECT imaging agents for the in vivo detection of Ab plaques in Alzheimer's brains.
PET Probes for Imaging of Ab b Plaques Derived from Stilbene and Benzofuran
As part of efforts to develop 11 C-labeled tracers for PET imaging of Ab plaques in AD, we have evaluated a series of simple molecular probes. The minimum requirements for a successful Ab-plaque-specific imaging agent include: small, neutral molecules; sufficient but moderate lipophilicity, good brain penetration; and low nonspecific binding in regions of the brain with no Ab plaques. To meet the challenges of designing such molecules, we have investigated several series of core structures. One of them is a stilbene derivative, which is relatively simple and readily amenable to structural modification. A previous report suggested that the binding affinity to Ab aggregates is associated with the essential substitution groups at the 4-and 4Ј-positions of the two phenol rings on the stilbene. 22) To balance the need to preserve the binding affinity and provide compounds with moderate lipophilicity, we have studied a series of simple stilbenes with 4-amino and 4Ј-hydroxy substitution groups (Table 1 ).
An in vitro binding assay using preformed Ab(1-40) aggregates demonstrated that substituted stilbenes (1-6) competed with [ 125 I]TZDM, binding to Ab(1-40) aggregates with excellent binding affinities. Among the stilbenes evaluated, it is evident that N-mono-methylated (3, 4) or N,Ndimethylated (5, 6) derivatives displayed higher binding affinities (K i ϭ1-6 nM). We are interested in selecting a compound with moderate lipophilicity and high binding affinity. To fulfill the need for opposing molecular properties, compound 4, (K i ϭ6 nM) was selected as a compromise choice for 11 C labeling and further testing (Table 1) .
In vitro autoradiography was performed by incubating [
11 C]4 with brain sections from control and double-mutation mice (TgCRDN8). 23, 24) Using brain sections from these mice, Ab plaque labeling by [
11 C]4 was tested. The labeled stilbene derivative, [ 11 C]4, showed an excellent binding to plaques in the mutant mouse brain sections, while only minimal labeling in control sections was observed (Fig. 2) .
To examine the in vivo brain penetration, normal rats were injected with [
11 C]4, and cortex and cerebellar regional brain tissue uptakes were determined at different time points (Table 2 ). The initial brain uptake in the rat cortex was relatively high (1.15% dose/g, 2 min after intravenous (i.v.) injection), whereas the retention of [ 11 C]4 in the brain was low (0.3% dose/g, 60 min after i.v. injection). A rapid washout rate suggests that the compound has low nonspecific binding in the brain, a highly desirable property for an Ab imaging probe. Taken together, the data strongly suggest that the new 11 C-labeled stilbene compound, [ 11 C]4, may be a useful PET tracer for imaging Ab plaques in the brain of patients with AD. 9) In an attempt to develop more useful Ab-specific imaging agents, we investigated a novel series of benzofuran derivatives, designed to be isosteric analogues of thioflavin-T (ThT) (Fig. 3) . 25) We reported previously that iodinated benzofuran derivatives displayed excellent binding affinities for Ab(1-40) aggregates (K i ϭ0.4-9.0 nM) and good brain penetration (Ͼ1.1% injected dose (ID) after i.v. injection in normal mice). However, the in vivo nonspecific binding of these probes, as reflected by their slow washout from the normal mouse brain, made them unsuitable for in vivo Ab 26) These previous findings suggested that additional structural changes to these benzofurans may lead to the development of useful amyloid-specific imaging agents. Then, we designed and synthesized a new series of benzofuran derivatives (7) (8) (9) (10) (11) (12) Next, compound 10 was investigated for its neuropathologic staining of SPs in human AD brain sections (Fig. 4) . Compound 10 stained neuritic plaques, as well as cerebrovascular amyloid (Fig. 4 , panels A and B). Since it is commonly assumed that neuritic plaques are formed even in very mild AD cases, and that the density of the neuritic plaques is associated with the severity of dementia and the number of neurons, 27, 28) clear staining of Ab plaques with compound 10 demonstrates that it is a promising compound and deserves further investigation as a potential tool for early diagnosis. Furthermore, compound 10 also displayed high binding affinity for NFTs in AD brain sections (Fig. 4C) . A previous study reported that a marked increase in the amount of NFT accumulation in the hippocampus and entorhinal cortex was observed in the preclinical AD stage. 29) Because compound 10 intensely stained NFTs in human AD brain sections, it could detect increased NFT accumulation in the hippocampus and entorhinal cortex of the AD brain. These findings from the neuropathologic staining of human AD brain sections suggest that compound 10 can bind to Ab plaques and NFTs with almost the same pattern of FDDNP 14) or X-34 30) previously reported, and quantitative evaluation of radiolabeled compound 10 in the brain may provide useful information on Ab and tau pathology.
To predict the permeability of the blood-brain barrier (BBB), a 1-octanol/phosphate buffer (pH 7.4) partition coefficient of [ 11 C]10 was examined. The log P value of [ 11 C]10 was 2.36 at pH 7.4. Previous studies suggested that the optimal lipophilicity range for brain entry is observed for compounds with log P values between 1 and 3. 31) Below that range, passive diffusion through the BBB is poor; above that range, binding of any radiotracers to blood components (e.g., red blood cells and albumin) is so great as to limit the amount available for brain entry. Since this ligand displayed moderate lipophilicity for BBB penetration, it was expected to show adequate brain uptake to detect Ab plaques following systemic injection.
A biodistribution study in normal mice after intravenous injection showed that [ 11 C]10 exhibited excellent brain uptake (4.8% ID/g of the brain at 2 min) and rapid washout (0.4 and 0.2% ID/g of the brain at 30 and 60 min, respectively), while the blood levels were relatively low at all time points measured (Table 4) .
[ 11 C]PIB is currently the most widely utilized for detecting Ab plaques in AD patients. 6, 32, 33) More recently, it has been reported that [ 
SPECT Probes for Imaging of Ab b Plaques Derived from Flavonoid Compounds
Flavone-Based Ab b Imaging Probes It is well known that PET provides better functional information with higher resolution and greater sensitivity than SPECT. However, since SPECT imaging is more practical as a routine clinical diagnostic procedure, the development of Ab imaging agents for SPECT has been highly anticipated. In an attempt to develop 123 I tracers for SPECT imaging, many radioiodinated probes based on various core structures have been studied. Among the radioiodinated ligands, [ 123 I]IMPY ( Fig. 1) has been characterized as a potential SPECT imaging agent for Ab plaques. 18, 19) IMPY displayed selective Ab plaque labeling in ex vivo autoradiography using double-transgenic mice (PSAPP) as a model of AD. 20) In addition, 2-(3Ј-iodo-4Ј-aminophenyl)-6-hydroxybenzothiazole (6-OH-BTA-O-3Ј-I) also showed desirable in vitro and in vivo properties. 34) However, clinically useful SPECT imaging agents have not been reported in humans.
Recently, the effects of polyhydroxyflavones on the formation, extension, and destabilization of Ab aggregates have been studied in vitro. 35) These flavones dose dependently inhibited the formation of Ab aggregates, as well as destabilizing preformed Ab aggregates, indicating that they could interact directly with Ab aggregates. The findings in that previous report prompted us to apply flavones as a novel core structure of Ab imaging agents. Furthermore, some recent studies have shown that electron-donating groups such as methylamino, dimethylamino, methoxy, and hydroxy groups play a critical role in the binding affinity to Ab aggregates.
5,9,19,22,26,36) With these considerations in mind, we designed four radioiodinated flavones with a radioiodine at the 6-position and an electron-donating group at the 4Ј-position (Fig. 6 ). Then we synthesized a series of flavone derivatives and evaluated their usefulness as in vivo SPECT Ab imaging agents. high K i values (Ͼ1000 nM) were observed (Table 5) , indicating poor binding competition. This finding suggests that these flavones may have a binding site on Ab aggregates different from that of ThT and CR, although additional studies regarding the selectivity of binding affinity for Ab aggregates are required.
Since the in vitro binding assays demonstrated the high binding affinity of the flavone derivatives for Ab(1-40) and Ab(1-42) aggregates, compounds 13, 14, 15, and 16 were investigated for their neuropathologic staining of Ab plaques and NFTs in human AD brain sections (Fig. 8) sections may be relevant to the phenomenon observed in the in vitro binding assay: they may occupy a binding site on Ab aggregates different from that of ThT and CR. Such a binding characteristic of the present flavone derivatives is thought to be related to the recent finding that a similar compound with a flavone backbone structure has binding affinity with amyloid fibrils and the APP sequence. 38) However, this issue regarding the binding property of flavone derivatives remains unresolved. These flavone derivatives appear to stain not only neuritic amyloid plaque but also diffuse amyloid plaque deposits, which are known to be mainly composed of Ab(1-42) 39) and to be the initial pathologic change in AD. 40) (Figs. 8D, H, L 26) reported previously showed high brain uptakes, but the washout rates from the normal brain were relatively slow. The slow washout rate from the brain leads to high background activity and prevents the visualization of Ab plaques in the AD brain. The appropriate in vivo properties observed for radioiodinated flavones in the present study (higher brain uptake and faster washout from the normal brain) make them useful candidates for SPECT tracers for Ab imaging.
Chalcone-Based Ab b Imaging Probes To search for more useful candidates in the development of in vivo Ab imaging probes, we have designed a chemical modification of the flavone structure and selected the chalcone structure as a novel core for Ab imaging probes (Fig. 9) . 42, 43) Chalcone is categorized as a member of the flavonoids containing flavone and has a chemical structure in which the ether linkage is removed from the flavone structure. Chalcone also contains a moiety structurally similar to curcumin (Fig. 9) , which has been reported to have good brain permeability and favorable binding affinity to Ab plaques after intravenous administration in Tg2576 transgenic mice. 44, 45) Recently, radiolabeled curcumin derivatives have also been reported as Ab imaging probes. 46) In addition to the structural characteristics of chalcone as the pharmacophore, some recent studies have shown that electron-donating groups such as amino, methylamino, dimethylamino, methoxy, or hydroxy groups play a critical role in the binding affinity to Ab aggregates. 9, 22, 26, 36) We therefore designed and synthesized novel chalcone derivatives and related chalcone-like compounds (17-39) (Fig.  10) , and evaluated the effect of their structure-activity relationships on the binding affinity to Ab aggregates and in vivo biodistribution using a compound with high binding affinity.
( 
Aurone-Based Ab b Imaging Probes
To explore more useful candidates for core structures of Ab imaging probes, we selected one of the flavonoids, aurone, as a new core structure. First, we synthesized a series of aurone derivatives, which possess a radioiodine at the 5-position and a nucleophilic group (NH 2 , NHMe, NMe 2 ) at the 4Ј-position, and evaluated their biological activities as in vivo Ab imaging probes (Fig. 12) . 47) To evaluate the binding affinity of aurone derivatives to Ab aggregates, a saturation assay with [ 125 I]40 was carried out using Ab(1-42) aggregates. When the saturation bindings of [ 125 I]40 were transformed to Scatchard plots, they showed linear plots, indicating that aurone derivatives have one binding site on Ab aggregates (Fig. 13) (Table 9 ). The K i values estimated for 40, 41, and 42 were 2.7, 1.2, and 6.8 nM for Ab(1-42) aggregates, respectively. These K i values suggested that the new series of aurones had excellent binding affinity for Ab(1-42) aggregates and showed considerable tolerance for structural modification. The K i values of the radioiodinated aurones reported previously were lower than those of the radioiodinated flavones, indicating that the radioiodinated aurones have higher binding affinities to Ab plaques than those of the corresponding radioiodinated flavones and chalcones.
To confirm the binding affinity of aurone derivatives to Ab plaques in the brain, neuropathologic flurorescent staining with compound 42 was carried out using double-transgenic Alzheimer's mouse brain sections (Fig. 14) . Many Ab plaque deposits were clearly stained with compound 42, as reflected by the high binding affinity to Ab aggregates in in vitro competition assays. The compound clearly stained not only core plaques, but also typical senile plaques. The labeling pattern was consistent with that observed with immunohistochemical labeling with an antibody specific for Ab, indicating that aurone derivatives show specific binding to Ab plaques. Thus the results suggest that aurone derivatives may be applicable for in vivo imaging of Ab plaques in the brain.
To evaluate the brain uptake of the aurone derivatives, in vivo biodistribution studies in normal mice were performed with three radioiodinated aurones ([ (Table 10 ). The aurone derivatives displayed high brain uptake rates ranging from 1.9-4.6% ID/g brain at 2 min postinjection, indicating a level sufficient for Ab imaging of the brain. In addition, they displayed rapid clearance from the normal brain with 0.49%, 0.32%, and 0.26% ID/g at 30 min postinjection for [ ]42, respectively. We reported that radioiodinated flavones showed high brain uptake (3.2-4.1% ID/g at 2 min postinjection) and good clearance from the brain (0.5-1.9% ID/g at 30 min postinjection). However, the ratios of 2-to 30-min mouse brain uptake of the radioiodinated flavones were 40.0%, 44.6%, and 57.8% for NH 2 , NHMe, and NMe 2 derivatives, respectively, which were higher than those of radioiodinated aurones. The result suggests that aurone derivatives do not show high nonspecific binding in the brain in vivo. These desirable pharmacokinetics demonstrated by radioiod- inated aurones are critical to detect Ab plaques in the AD brain. These biodistribution data suggest that novel radioiodinated aurones may have more suitable in vivo pharmacokinetic properties for Ab imaging in AD brains compared with the radioiodinated flavones and chalcones. However, these aurone derivatives appeared inferior to IMPY in pharmacokinetics, although their high affinity for Ab plaques is sufficient for imaging in vivo. Therefore additional structural changes are essential to improve the properties of aurone derivatives to make them suitable for the imaging of Ab plaques in the brain.
To develop more promising aurones for SPECT-based imaging of Ab plaques, we designed a novel series of radioiodinated derivatives with polyethylene glycol (PEG). 48) PEG is nontoxic, nonimmunogenic, highly soluble in water, and FDA approved, and PEGylation has been used to change the pharmacokinetics of various biologically interesting proteins or peptides, leading to better therapeutics. 49, 50) Therefore PEGylated aurone derivatives are worthy of further evaluation as novel Ab imaging probes for SPECT.
We designed and synthesized a novel series of radioiodinated aurone derivatives with not only 1 to 3 units of ethylene glycol at the 4Ј position, but also other nucleophilic groups (-OCH 3 and -OH) (Fig. 12 ) and evaluated their biological potential as probes for imaging Ab by testing their affinity for Ab aggregates in vitro and their uptake by and clearance from the brain in biodistribution experiments using normal mice.
Our initial screening of the affinity of aurone derivatives (43, 44, 45, 46, 47) was carried out with Ab(1-42) aggregates, using [ 125 I]AAU as the competing radioligand (Table  11 ). The K i values estimated for 43, 44, 45, 46, and 47 were 2.9, 1.3, 1.1, 3.4, and 2.6 nM, respectively. These values suggested that the new series of aurone derivatives had binding affinity for Ab(1-42) aggregates despite their substituted groups. The binding affinity is in the same range as that of aurone derivatives possessing a nucleophilic group (NH 2 , NHMe, NMe 2 ). 47) These results clearly indicate that aurone derivatives exhibit considerable tolerance to structural modifications. The binding affinity of aurone derivatives is very close to that of known Ab imaging probes such as SB-13 (K i ϭ1.2 nM), 51) PIB (K i ϭ2.8 nM), 52) and IMPY (K i ϭ 1.4 nM), 51) indicating that they have sufficient affinity to test clinically.
To confirm the affinity of aurone derivatives for Ab plaques in the mouse brain, neuropathologic fluorescent staining with 43, 44, 45, 46, and 47 was carried out using double-transgenic Alzheimer's mouse brain sections (Fig.  15) . Many Ab plaque deposits were clearly stained with the derivatives, as reflected by the high binding affinity for Ab aggregates in in vitro competition assays. The labeling pattern was consistent with that observed with ThS. These results suggest that novel aurone derivatives show affinity for Ab plaques in the mouse brain in addition to having binding affinity for synthetic Ab42 aggregates.
To evaluate brain uptake of the aurone derivatives, biodistribution experiments were performed in normal mice with five radioiodinated aurones ( (Table 12 ). Radioactivity after injection of the aurone derivatives penetrated the BBB and showed excellent uptake ranging from 1.7 to 4.5% ID/g brain at 2 min postinjection, a level sufficient for imaging Ab plaques in the brain. In addition, it displayed good clearance from the normal brain with 0.1-0.4% ID/g at 30 min postinjection. One method to select a ligand with appropriate in vivo kinetics is to use brain 2 min /brain 30 45 had the best washout index. Previously reported radioiodinated aurones showed high uptake (1.9-4.6% ID/g at 2 min postinjection) and good clearance from the brain (0.3-0.5% ID/g at 30 min postinjection). 48) However, the brain 2 min /brain 30 min ratios of these compounds were 7.3-9.9, lower than that of [ Fig. 16C ), correlating well with the absence of Ab plaques (Fig. 16D ). These results demonstrate the feasibility of using [ 
Conclusion
We successfully designed and synthesized several basic structures that can function as useful Ab imaging probes. We hope that the Ab imaging probes will contribute to improved diagnosis and accelerate the discovery of effective therapeutic agents for AD in the near future. P., Bergstrom M., Savitcheva I., Huang G. F., Estrada S., Ausen B., 
